Peter Soparkar

All filings by Peter Soparkar on record concern Adverum Biotechnologies, Inc., in the capacity of chief executive. Over a trading history stretching from 6 August 2021 to 9 December 2025, the count stands at 9 filings.

The open-market side counts 3 purchases for €224k alongside 3 sales for €29k. The net balance comes to €195k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants. Since January 2025: 1 purchase and 1 sale on the market.

In size, the median ticket on the buying side is €42k. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 10 December 2025: a transaction, in Adverum Biotechnologies, Inc. The last insider purchase was made public on 8 December 2025, 314 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.